Form 4: Nanophase Technologies Director Janet Whitmore Reports Changes in Beneficial Ownership

Sentiment:

SEC Form 4


Director Janet Whitmore reports changes in beneficial ownership of Nanophase Technologies Corp shares, including the acquisition of stock options.

Delay expectedThe report was filed late due to an administrative error on the part of the company.

Summary

  • Janet Whitmore, a director of Nanophase Technologies Corp, filed a Form 4 detailing changes in her beneficial ownership.
  • The report includes the acquisition of 12,000 common stock options at an exercise price of $2.44 on December 31, 2024.
  • Whitmore directly owns 2,049,142 shares of common stock.
  • She also holds derivative securities including options to purchase common stock at various exercise prices and expiration dates.
  • The filing notes a delay due to an administrative error by the company and clarifies that the stock options were granted as part of the company's annual equity compensation practices.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock ownership changes. The late filing is a minor negative, but the explanation mitigates concern.

Negatives

  • The report was filed late due to an administrative error on the part of the company.

Risks

  • The late filing, although attributed to an administrative error, could raise concerns about compliance with reporting requirements.

Management Comments

  • Ms. Whitmore received this grant of stock options as part of the Company's annual equity compensation practices.

Industry Context

Director ownership and stock option grants are common practices in publicly traded companies to align the interests of management and shareholders. This filing is a routine disclosure related to these practices.

Stakeholder Impact

  • The disclosure provides transparency to shareholders regarding the equity ownership of a key company director.

Key Dates

DateDescription
11/17/2016Date of stock appreciation rights, later converted to stock options with an exercise price of $1.85, expiring on 11/17/2026.
12/28/2022Date of stock options grant with an exercise price of $4.17, expiring on 12/28/2028.
12/20/2023Date of stock options grant with an exercise price of $1.165, expiring on 12/20/2029.
12/27/2024Date of stock options grant with an exercise price of $0.61, expiring on 12/27/2030.
12/31/2024Date of transaction: acquisition of 12,000 common stock options with an exercise price of $2.44, exercisable until 12/31/2031.
01/13/2025Date of filing the Form 4.
12/31/2025Date of stock options grant with an exercise price of $2.44, expiring on 12/31/2031.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.